Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Carbon to carbon unsaturation

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514553000 - Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI

514557000 - Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)

514558000 - Higher fatty acid or salt thereof

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130046020EICOSAPENTAENOIC ACID CONCENTRATE - An omega-3 oil concentrate comprising at least 70 weight percent of eicosapentaenoic acid [“EPA”; cis-5,8,11,14,17-eicosapentaenoic acid; omega-3], measured as a weight percent of oil, and substantially free of docosahexaenoic acid, said concentrate obtained from a microbial oil having 30 to 70 weight percent of eicosapentaenoic acid, measured as a weight percent of total fatty acids, and substantially free of docosahexaenoic acid and wherein said microbial oil is obtained from a microorganism that accumulates in excess of 25% of its dry cell weight as oil. Also disclosed are methods of making such eicosapentaenoic acid concentrates.02-21-2013
20120184618TEAT DIP CONCENTRATE - A concentrated iodine-free teat dip composition is provided including sulfonated oleic acid, a metal chelant, and an aqueous acidulant wherein the diluted use solution has a pH of less than 2.7. A method of treating mastitis is provided including applying the diluted concentrate on an animal's teats. Applying is accomplished by dipping the teats into a liquid solution, spraying the use solution onto the teats, or dipping the teats into or spraying onto the teats a diluted foamed composition of the concentrate.07-19-2012
20090258945Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders - Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.10-15-2009
20090192226Materials and Methods for Treatment of Pathological Ocular Vascular Proliferation - The subject invention provides for the administration of docosahexaenoic acid in preventing pathological proliferation of blood vessels. The compositions of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.07-30-2009
20110196038Bipolar trans carotenoid salts and their uses - The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.08-11-2011
20110196037USE OF NITRATED LIPIDS FOR TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES - The present invention relates to methods of treating the side effects of a toxic medical therapy using nitrated lipids. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.08-11-2011
20120245229METHOD FOR TREATING NEUROPATHIC PAIN - The invention describes a method to treat neuropathic pain and/or inflammatory pain, comprising the step of administering to a subject in need thereof an effective amount of a resolvin, such that neuropathic pain and or inflammatory pain is treated.09-27-2012
20130079409STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.03-28-2013
20100010088Compositions and Methods for Prevention and Treatment of Mammalian Diseases - The present invention discloses processes of making a polyunsaturated fatty acid compositions, and compositions thereof. Thus, one method of making a polyunsaturated fatty acid compositions comprises at least 8% polyunsaturated fatty acids, the process comprising extracting the fatty acids from a microalgae, wherein the fatty acids can be (a) GLA in an amount of 1% to 10% of total fatty acids; (b) SDA in an amount of 5% to 50% of total fatty acids; (c) EPA in an amount of 2% to 30% of total fatty acids, and (d) DHA in an amount of 2% to 30% of total fatty acids, wherein a polyunsaturated fatty acid composition is produced comprising at least 8% polyunsaturated fatty acids. Additional processes of making polyunsaturated fatty acid compositions, animal feed additives, and animal products are disclosed and the compositions, feed additives and products thereof.01-14-2010
20130137771FATTY ACIDS FOR USE AS A MEDICAMENT - The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. 05-30-2013
20130041031FATTY ACID DESATURASES FROM PRIMULA - The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are 02-14-2013
20130041032FATTY ACID DESATURASES FROM PRIMULA - The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are 02-14-2013
20130210916THERMALLY STABLE OIL-IN-WATER EMULSIONS CONTAINING AN OIL THAT CONTAINS POLYUNSATURATED FATTY ACIDS - The present invention relates to thermally, stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of −40° C., and are free from a variation in particle size after 9 months in storage at a temperature of −40° C. to −15° C.08-15-2013
20130210917Nitrated Lipids and Methods of Making and Using Thereof - Described herein are nitrated lipids and methods of making and using the nitrated lipids.08-15-2013
20090264528SERINE PALMITOYLCOA TRANSFERASE (SPT) INHIBITION BY MYRIOCIN OR GENETIC DEFICIENCY DECREASES CHOLESTEROL ABSORPTION - A first aspect of the invention provides a method of screening cholesterol absorption inhibitors, including: administering to a mammal a biologically effective amount of a candidate SPT inhibitor; and determining whether an amount at least one cholesterol absorption indicator protein in the intestine has changed after the administering step.10-22-2009
20100041755FATTY ACID TREATMENT FOR CARDIAC PATIENTS - A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.02-18-2010
20120065264SELF-EMULSIFYING COMPOSITION OF w3 FATTY ACID - This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.03-15-2012
20100105773USE OF RESOLVINS AND DOCOSATRIENES AND ANALOGUES THEREOF FOR THE TREATMENT OF ANGIOGENESIS AND OCULAR NEOVASCULARIZATION - The present invention relates to methods and compositions for the treatment of, or prevention of angiogenesis in a subject. In particular, the present invention relates to methods to treat a subject with, or at risk of developing angiogenesis by administering a pharmaceutical composition comprising a resolvin or resolvin analogue or precursor, and/or a protectin or protectin analogue. In another embodiment, the present invention relates to the use of resolvins and protectins to treat pathologies associated with angiogenesis.04-29-2010
20090149539PET FOOD COMPOSITIONS AND METHODS - Presently described are compositions and methods which utilize stearidonic acid (SDA).06-11-2009
20100331415USE OF OMEGA-3-FATTY ACID(S) - The invention relates to the use of omega-3-fatty acid(s) in means for pain relief. The means preferably comprise highly unsaturated omega-3-fatty acid(s) that contain, above all, EPA and/or DHA. Preferably, the omega-3-fatty acid is administered in a high dose of more than 2 g, in particular more than 3 to 4 g, for pain relief.12-30-2010
20130090383STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.04-11-2013
20090326070VINYL SUBSTITUTED FATTY ACIDS - Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.12-31-2009
20100267830METHODS AND COMPOSITIONS FOR PROMOTING THE NEUROLOGICAL DEVELOPMENT OF AN INFANT - The present invention relates to methods for promoting the neurological development of an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.10-21-2010
20090203787VERY LONG CHAIN POLYUNSATURATED FATTY ACIDS, METHODS OF PRODUCTION, AND USES - The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements and food products) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described herein (particularly C28-C38 PUFAs, also referred to herein as supraenes or supraenoics) by the expression, in a production host cell, of the full or partial sequence(s) of Elovl4 DNA/mRNA nucleic acids or ELOVL4 protein sequences encoded thereby, from any species (prokaryotic or eukaryotic) for use in the biosynthesis, production, purification and utilization of VLC-PUFAs in particular by the elongation of C18-C26 saturated fatty acids and PUFAs. The composition of the invention comprises, in various embodiments, a dietary supplement, a food product, a pharmaceutical formulation, a humanized animal milk, an infant formula, a cosmetic item and a biodiesel fuel for example. A pharmaceutical formulation can include, but is not limited to: a drug for treatment of neurodegenerative disease, a retinal disorder, age related maculopathy, a fertility disorder, particularly regarding sperm or testes, or a skin disorder.08-13-2009
20130059912NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES - Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.03-07-2013
20090281185CRYSTALLINE LEUKOTRIENE B4 - Leukotriene B11-12-2009
20090270504Treatment of Huntington's Disease With EPA - Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.10-29-2009
20090270503NUTRITIONAL SUPPLEMENTS - The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provides improved nutritional support for women prior to and during lactation. Further the methods and compositions improve gestational length and birth weight. The nutritional methods and compositions are also intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.10-29-2009
20120225945COMPOSITIONS COMPRISING A FATTY ACID OIL MIXTURE AND A SURFACTANT, AND METHODS AND USES THEREOF - A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.09-06-2012
20090234008Method of using catalpic acid to treat and prevent dyslipidemia, type 2 diabetes, and associated disorders - A method of treating and preventing dyslipidemia, cardiovascular disease, type 2 diabetes, obesity and other diseases associated with the Metabolic Syndrome and of increasing the expression of genes that promote lipid oxidation in an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid is administered orally or parenterally to the animal.09-17-2009
20100035989COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS - The invention relates to methods of treating mucositis comprising administering a compound of formula A, compound of any one of formulae 1 to 46, lipoxin compound, or oxylipin compound.02-11-2010
20120232145COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES IN A SUBJECT ON CONCOMITANT STATIN THERAPY - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.09-13-2012
20090012167Omega-3 Fatty Acids and Dyslipidemic Agent for Lipid Therapy - A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.01-08-2009
20090012166Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These - The present invention relates to new substances which are derived from naturally occurring straight-chain and unbranched fatty acids and also from semi-synthetic and synthetic compounds with principally the same structure in that they represent dimers, trimers, tetramers or higher oligomers of the starting substances.01-08-2009
20120238626Methods and compositions for promoting the respiratory development of an infant - The present invention relates to methods for promoting respiratory development, reducing the incidence of respiratory distress, bronchopulmonary dysplasia and/or hayfever in an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.09-20-2012
20120238625BIOLOGICALLY ACTIVE OILS - A process for the production of fats or oils and their extracts containing biologically active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes; b) incubating the inoculated substrate for a period of between about 7-120 days at a temperature of between about 4-35° C., at a humidity of between about 75-100%, and c) processing said substrate mixture to obtain a biologically active fat or oil.09-20-2012
20090099261Omega-3 mixtures - The present invention is directed to mixtures of omega-04-16-2009
20090105341PROCESS FOR THE PRODUCTION OF TRANS-10, CIS 12 OCTADECADIENOIC ACID - The present application is directed to a process for the production of trans-10, cis-12 conjugated linoleic acid in a transgenic microorganism comprising the steps of: (a) introducing into said microorganism at least one nucleic acid molecule encoding a trans-10, cis-12 conjugated linoleic acid isomerase, (b) culturing the transgenic microorganism obtained under (a), (c) inducing the production of trans-10, cis-12 conjugated linoleic acid by adding linoleic acid to the culture, (d) incubating the induced culture for at least 12 hours, and (e) isolating the conjugated linoleic acid from the culture media and/or transgenic microorganism.04-23-2009
20090082447Pharmaceutical Compositions Containing Omega 3 Fatty Acids - Pharmaceutical composition comprising a liquid oil rich in omega-3 polyunsaturated fatty acids which is absorbed on a silica-type support. The composition so obtained has the characteristics of a powder when the oil:silica ratio is of the order of 3:1 while at the same time allowing the required daily dose of omega-3 fatty acids to be delivered in one or more unit doses. The composition according to the invention can be used in the manufacture of oral pharmaceutical forms such as hard capsules.03-26-2009
20090156675COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.06-18-2009
20120122981Biomarkers Related to Insulin Resistance and Methods using the Same - Biomarkers relating to glucose disposal rate, insulin resistance, and/or insulin resistance-related disorders are provided. Methods based on the same biomarkers are also provided.05-17-2012
20090182051COSMECEUTICAL FORMULATION CONTAINING PALM OILS - A cosmeceutical formulation is provided that includes a mixture of a refined, bleached, deodorized (RBD) palm oils and red palm olein. The resulting formulation is a homogeneous blend with a considerable shelf life. The formulation may be a cream, lotion, sunscreen, or a soap and may be formulated to include additional beneficial oils and EFAs. If a cream formulation is desired, RBD palm stearin is the preferred palm oil for producing a creamy texture. If a lotion is desired, RBD palm oil may be used and chemically modified to produce a tailored oil with a desired melting point and consistency. The formulation may be used to treat a variety of skin conditions including adverse and age-related skin conditions or as an effective moisturizer for the prolonged maintenance of ordinary skin.07-16-2009
20110301239USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.12-08-2011
20110130459COMPOSITION FOR ACCELERATED PRODUCTION OF COLLAGEN - Here the inventors provide a composition for topical application to the skin of animal comprising stearidonic acid in combination with one or octadecatrienoic acids (CODTAs). Preferably the composition comprises 06-02-2011
20120016028METHOD OF PREPARING AN UNSATURATED FATTY ACID DRY CONCENTRATE - There is provided a method of preparing an unsaturated fatty acid dry concentrate, wherein a substance comprising at least one unsaturated fatty acid is applied on a biologically inert matrix having a large surface area and is subsequently dried, as well as a composition comprising at least one unsaturated fatty acid and foods, beverages, drugs comprising this composition.01-19-2012
20110294884Bipolar trans carotenoid salts and their uses - The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.12-01-2011
20110294883ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS INTENDED FOR USE AS A DRUG - Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.12-01-2011
20100152293USE OF POLYUNSATURATED KETONES FOR THE TREATMENT OF PSORIASIS - Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X) (Wherein R is a C06-17-2010
20090082446Use of Hydroxyoleic acid and related compounds in the manufacture of drugs - Use of hydroxyoleic acid and its analogous compounds in the manufacture of drugs. Describes the use of hydroxyoleic acid and its analogs of general formula I: COOH—CHR—(CH03-26-2009
20100004334Nutritional Compositions Containing Punicalagins - The present invention relates generally to a nutritional composition comprising punicalagins.01-07-2010
20100035990ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) - Omega-3 lipid compounds of the general formula (I):02-11-2010
20110201683OIL CONTAINING ONE OR MORE LONG-CHAIN POLYUNSATURATED FATTY ACIDS PHOSPHOLIPIDS DERIVED FROM BIOMASS - The present invention relates to a method to extract long-chain polyunsaturated fatty acids from sources using emulsifiers dispersed in oil as carrier and to the oils obtainable from such a method. It also relates to the use of emulsifier in oil for improving the extraction of long-chain polyunsaturated fatty acids in the form of phospholipids and, in a further aspect, to an oil composition comprising long-chain polyunsaturated fatty acids in an amount up to 4% and phospholipids in an amount up to 15% and at least one emulsifier.08-18-2011
20100120914MEDICAMENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF HEPATIC STEATOSIS OR NON-ALCOHOLIC STEATOHEPATITIS - A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.05-13-2010
20100249232MOSQUITO REPELLENT - The present invention relates to a mosquito repellent comprises at least one or more selected from the group consisting of neric acid and derivatives thereof in an effective amount to repel mosquito.09-30-2010
20100261793METHOD FOR DECREASING CARTILAGE DAMAGE IN DOGS - A method for modulating enzymatic degradation of articular cartilage in a dog comprises administering to the dog an enzymatic degradation modulating effective amount of eicosapentaenoic acid (EPA), for example as a component of a food composition. By practice of the method in a dog having arthritis, mobility of the dog can be increased, weight bearing in an arthritic limb can be increased, and/or pain associated with arthritis can be reduced.10-14-2010
20080207756Bio-absorbable oil suspension - Exemplary embodiments of the invention provide a dispersing liquid for coating internal body tissues with a bio-absorbable oil, a method of making the dispersing liquid, methods of using the dispersing liquid and a kit for coating internal body tissues using the dispersing liquid. The dispersing liquid includes a suspension of a bio-absorbable oil suspended in a liquid carrier. The invention results in a uniform thin coating of bio-absorbable oil on internal body tissues.08-28-2008
20120108663METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.05-03-2012
20100099765COMPOSITIONS, METHODS, AND KITS FOR POLYUNSATURATED FATTY ACIDS FROM MICROALGAE - The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and/or omega-6 fatty acids produced by members of the genus 04-22-2010
20090286879Preventive or Therapeutic Drug for Alzheimer-Type Dementia - It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ω-3 polyunsaturated fatty acid and thyroid hormone are used in combination.11-19-2009
20090292020USE OF CALCIUM SALT OF POLYENOIC ACID IN MEDICAL AND COSMETIC FIELD - The present invention relates to a process for applying calcium polyenoic acid to medical cosmetology, wherein calcium polyenoic acid, calcium octadecadienic acid and calcium calendic acid are made into ointment or oil-type spraying agent for curing burn, scald, sun burn, bedsore, ulcer, cold injury, trauma. The calcium polyenoic acid and auxiliary materials are made into medical aesthetics product not only for resisting crease, anti-acne, removing mottling, exfoliating scrub, reducing pores and scars, sunburn, abrasion, skin injury, cold injury, antifreezing, anti-cracking, anti-older, sunscreen, repairing and regeneration, repairing damaged skin owing to all kinds of reasons, but also for cosmetic whitening, moisturizing, promoting the growth of epithelial cells, hemorrhoids, rhinitis, repairing damaged organization, promoting cell growth, anti-inflammatory, pain relief, mosquito bites, regulating vascular obstruction, thrombosis, wound healing, inflammation, allergic rhinitis, preventing the artery atherosclerosis and thrombosis formation. The present invention is low cost, high safety and has no side effects for popularization.11-26-2009
20100130610DEODORIZATION AND STABILIZATION OF MARINE OILS - The invention relates to a process for the preparation of deodorized and stabilized food-grade marine oils by submitting marine oils to a counter-current steam distillation (CCSD) in a thin film column containing a structured packing and, if desired, adding antioxidant(s), to the food-grade marine oils thus obtained and to their uses in the food/feed, cosmetic and/or pharmaceutical industry.05-27-2010
20120295974TRANS-, TRANS-CONJUGATED LINOLEIC ACID COMPOSITIONS AND USE THEREOF - This invention relates generally to trans-,trans-conjugated linoleic acid compositions and use thereof, and in particular to trans-,trans-conjugated linoleic acid produced from photoisomerization of soy oil in the presence of an antioxidant, and used in pharmaceutical, nutraceutical and human and animal food compositions for improved health. The invention also relates generally to a method for treatment and prevention of health-related disorders of obesity by administration of pharmaceutical, nutraceutical and/or food compositions containing and/or prepared from trans-,trans-conjugated linoleic acid-rich soy oil.11-22-2012
20120295976COMPOSITION AND/OR METHOD FOR PREVENTING RECURRENCE OF STROKE - By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.11-22-2012
20120071558COMPOSITIONS OF VERY LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF USE - The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements, food products, and pharmaceutic compositions) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described herein (particularly C28-C40 PUFAs, also referred to herein as supraenes or supraenoics) by the expression, in a production host cell, of the full or partial sequence(s) of Elovl4 DNA/mRNA nucleic acids or ELOVL4 protein sequences encoded thereby, from any species (prokaryotic or eukaryotic) for use in the biosynthesis, production, purification and utilization of VLC-PUFAs in particular by the elongation of C18-C26 saturated fatty acids and PUFAs. The composition of the invention comprises, in various embodiments, a dietary supplement, a food product, a nutritional formulation, a pharmaceutical formulation, a humanized animal milk, an infant formula, and a cosmetic item and for example. A pharmaceutical formulation can include, but is not limited to: a composition for enhancing neural development and function, a drug for treatment of neurodegenerative disease, an ocular disorder, a retinal disorder, age related maculopathy, a fertility disorder, particularly regarding sperm or testes, or a skin disorder.03-22-2012
20110207821 Method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis - Embodiments of the invention comprise methods of reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 and circulating Myeloperoxidase levels by administering to subjects an effective amount of a dietary oil composition containing 20-90 wt % polyunsaturated fatty acids. Lowering oxidized low density lipoprotein-beta-2-glycoprotein complex and Myeloperoxidase levels may be an effective treatment of atherosclerosis.08-25-2011
20120232147PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.09-13-2012
20120232146Methods of and Systems for Producing Diesel Blend Stocks - A method for producing biofuels is provided. A method of making biofuels includes dewatering substantially intact algal cells to make an algal biomass, extracting neutral lipids from the algal biomass, and esterifying the neutral lipids with a catalyst in the presence of an alcohol. The method also includes separating a water soluble fraction comprising glycerin from a water insoluble fraction comprising fuel esters and distilling the fuel esters under vacuum to obtain a C16 or shorter fuel esters fraction, a C16 or longer fuel ester fraction, and a residue comprising carotenoids and omega-3 fatty acids. The method further includes hydrogenating and deoxygenating at least one of (i) the C16 or shorter fuel esters to obtain a jet fuel blend stock and (ii) the C16 or longer fuel esters to obtain a diesel blend stock.09-13-2012
20080280980Treatment and Prevention of Bone Loss Using Resolvins - The present invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolvin. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolvin are also provided that can be used to performed the inventive methods.11-13-2008
20080306156METHOD OF USING CATALPIC ACID TO TREAT AND PREVENT TYPE 2 DIABETES AND ASSOCIATED DISORDERS - A method of treating and preventing type 2 diabetes and obesity an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid to the animal is administered orally or parentally.12-11-2008
20080306157Therapeutic intervention to MIMIC the effect of caloric restriction - Methods are provided for promoting longevity and decreasing the incidence of aging associated pathologies (e.g., cancer) by the administration of one or more of the following LFFA: linoleic, oleic and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and CoA LFFA formulations are described which protect the organism from acute physical stress, tissue damage and hypoxia (either due to trauma or secondary to surgical procedures.12-11-2008
20080306154Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids - Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and/or diabetes.12-11-2008
20080312324Treatment of lung cells with histone deacetylase inhibitors - Lung disease, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma or acute and chronic bronchitis, can be treated with an oxyamide-containing compound.12-18-2008
20080312323Inhibition of TNF-alpha-Initiated Response - The impact of lipoxin A12-18-2008
20100280116LINOLEIC ACID ACTIVE AGENTS FOR ENHANCING PROBABILITY OF BECOMING PREGNANT - The present invention is directed to a methods and compositions for enhancing the probability that a subject will become pregnant. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a linoleic acid active agent, e.g., linoleic acid, a polyunsaturated fatty acid analog thereof, etc. Also provided are kits that find use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including but not limited to the treatment of infertility conditions.11-04-2010
20080269330Nutrition Containing Fat Blend - The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.10-30-2008
20090264529ACTIVATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS - Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.10-22-2009
20080269331Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events - The use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic acid (DHA, C.sub.22:6 .omega.-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.10-30-2008
20090149538Aspirin-Triggered Lipid Mediators - Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.06-11-2009
20110207820NOVEL CHRYSOCHROMULINA SPECIES, METHODS AND MEDIA THEREFOR, AND PRODUCTS DERIVED THEREFROM - An algal cell that is capable of surviving in fresh water and has a high fatty acid content, an algal culture including the algal cell, methods of growing the algal culture, algal growth media, and methods for selectively adapting the algal culture are provided.08-25-2011
20130217771RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.08-22-2013
20090197954Linoleic acid preparations for the topical treatment of male and female pattern androgenetic alopecia, age-related alopecia, and keratosis pilaris - A preparation for the topical application of linoleic acid to treat male and female androgenetic alopecia, age-related alopecia, and keratosis pilaris contains between about 0.1% and about 10%, preferably between about 1% and about 5%, and specifically about 2% linoleic acid by volume in its carrier vehicle. This acts to correct the local linoleic acid deficiency that exists in the follicles in these conditions and provides linoleic acid to suppress growth of Propionibacterium acnes with resultant reduction in its porphyrin production which in turn reduces microinflammation and altered keratinization that damages follicles and eliminates functioning follicles in alopecia and causes follicle plugging in keratosis pilaris.08-06-2009
20090197955METHODS OF IMPROVING DHA DEPOSITION AND RELATED FUNCTION AND/OR DEVELOPMENT - The present invention provides for improved deposition of DHA in human or animal tissues by incorporating healthy lipids containing stearidonic acid into humans or animal through prolonged food or feed, as well as through supplements, and therapeutics. Improved deposition of DHA through consumptions of edible compositions comprising stearidonic acid can be used to improve numerous indicators of health and development, including indicators of heart health, neurological function and development, and the Omega-3 Index in tissues.08-06-2009
20090099260Polyunsaturated Fatty Acid-Containing Solid Fat Compositions and Uses and Production Thereof - The present invention provides a solid fat composition that includes an oil having saturated fat and an oil having at least one long chain polyunsaturated fatty acid. In particular, the solid fat composition can have high levels of long chain polyunsaturated fatty acid and low to no presence of emulsifiers. In preferred embodiments, the polyunsaturated oil is an unwinterized microbial oil. The invention also relates to methods for making such compositions and food, nutritional, and pharmaceutical products comprising said compositions.04-16-2009
20090203786Methods and Composition for Improving Cognitive Function - Compositions and methods for enhancing cognitive function in animals are disclosed. The compositions and methods utilize long chain polyunsaturated fatty acids.08-13-2009
20090209644LIPOTOXICITY RELIEVING AGENT - In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid containing 18 to 22 carbon atoms and having a degree of unsaturation of 3 to 6 or a derivative thereof as its effective component.08-20-2009
20090247634Methods for identifying modulators of eoxin formation - A method for identifying a compound for modulating the formation of 14,15-LTC10-01-2009
20090247633NUTRIENT EXTRACTS DERIVED FROM GREEN PLANT MATERIALS - An extract from green plant materials includes controlled concentrations of nutritional components. In one embodiment, the nutritional components include at least one xanthophyll, at least one hydrocarbon carotene, and at least one fatty acid wherein the xanthophyll, hydrocarbon carotene, and fatty acid each have about equal weight percentages. In a one embodiment, the green plant is alfalfa, the xanthophyll is lutein, the hydrocarbon carotene is β-carotene, and the fatty acids include an omega-3 essential fatty acid, an omega-6 essential fatty acid, or a combination of the acids thereof.10-01-2009
20100273881LIPID COMPOSITIONS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS AND THE PROMOTION OF INTESTINAL DEVELOPMENT AND MATURATION - The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.10-28-2010
20100160435COMPOSITION OF N-3 FATTY ACIDS HAVING HIGH CONCENTRATION OF EPA AND/OR DHA AND CONTAINING N-6 FATTY ACIDS - A composition of long-chain polyunsaturated fatty acids containing at least 80% by weight of eicosapentaenoic acid (EPA, C20:5 n-3) and/or docosahexaenoic acid (DHA, C22:6 n-3) and at least 3% by weight of n-6 fatty acids, particularly C20:4 n-6 and C22:5 n-6, is reported. For a better chemical and biological characterization of the composition, the content of other C20, C21 and C22 n-3 acids different from EPA and DHA is preferably reduced to less than 3% by weight. In the composition all said acids are present in the form of free acids, or their salts, or C1-C3 alkyl esters. The described composition is useful for the production of a dietetic or pharmaceutical preparation useful for treatment of conditions sensitive to the action of EPA and DHA, particularly in subjects potentially exposed to bleeding problems or to problems caused by coagulation defects.06-24-2010
20090048339COMPOSITIONS OF CIS-9, TRANS-11 CONJUGATED LINOLEIC ACID AND VACCENIC ACID AND USES THEREOF - The invention relates to use of the cis-9, trans-11 isomer of conjugated linoleic acid or a salt or ester thereof (cis-9, trans-11 CLA) and vaccenic acid or a salt or ester thereof (VA) to treat or prevent conditions associated with one or more of leukocyte infiltration, eosinophilia, airway remodelling, bronchoconstriction, mucus hypersecretion, and lung and skin inflammation. The present invention also relates to a composition comprising cis-9, trans-11 CLA and VA and use of the composition to treat or pre-vent conditions associated with one or more of leukocyte infiltration, eosinophilia, airway remodelling, bronchoconstriction, mucus hypersecretion, and lung and skin inflammation. In particular, the medicinal uses, compositions and methods of the invention may be used to treat or prevent conditions such as asthma and dermatitis, and related disorders.02-19-2009
20130190399Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) - The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.07-25-2013
20100216885Orodispersible composition comprising polyunsaturated fatty acids without bad odor or taste - An orodispersible composition without bad odor, smell, or taste comprising polyunsaturated fatty acids (PUFA) and a disintegrant. The disintegrant is a solid dispersion comprising mannitol, xylitol, microcrystalline cellulose, crospovidone and dibasic calcium phosphate. A process of preparing the composition and its use as nutritional or dietary supplement for balancing the blood lipid level, preventing or reducing the risk of the development of atherosclerotic changes, disorders or diseases.08-26-2010
20130123361HIGH ARACHIDONIC ACID PRODUCING STRAINS OF YARROWIA LIPOLYTICA - Engineered strains of the oleaginous yeast 05-16-2013
20130123362TYPE A GELATIN CAPSULE CONTAINING PUFA IN FREE ACID FORM - A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.05-16-2013
20100240753EFFECTIVE PHARMACEUTICAL CARRIER FOR POORLY BIOAVAILABLE DRUGS - The present invention is directed to an improved effectiveness pharmaceutical carrier comprising anyone or a combination of edible or pharmaceutical acceptable fatty acids and anyone or a combination of non-ionic surfactants, which is capable of improving the bio-absorption of drugs with intermediate log P ranging from 2 to 4 (having poor solubility in both water and triglycerides) as well as those with high log P of more than 4.09-23-2010
20100144878Nutritional supplement or functional food comprising oil combination - The present invention relates to a nutritional supplement or functional food comprising or consisting of (a) a nut oil in an amount of 0.5 to 20 percent by volume; (b) one or more ω-3-fatty acid sources in an amount of 10 to 50 or 10 to 90 percent by volume, the total amount of ω-3-fatty acids in each of the ω-3-fatty acid sources being at least 20 percent by volume; and (c) a flavour carrier in an amount of 10 to 89.5 percent by volume. Additionally the present invention relates to salad dressing consisting of or comprising the nutritional supplement or functional food of the invention. Finally the present invention relates to the use of the nutritional supplement or functional food of the invention as salad dressing.06-10-2010
20100216884NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES - Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.08-26-2010
20120196934COMPOSITIONS COMPRISING A FATTY ACID OIL MIXTURE COMPRISING EPA AND DHA IN FREE ACID FORM AND A SURFACTANT, AND METHODS AND USES THEREOF - Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.08-02-2012
20120142776METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY - Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition.06-07-2012
20100087533COMPOSITION - A phytochemical composition for use as a veterinary dietary supplement comprising alpha linolenic acid (ALA) and up to 10% gamma linolenic acid (GLA). Preferably the ALA source is flax seed oil and GLA is sourced from borage oil.04-08-2010
20090253791Compositions and Methods For Preventing Or Treating Inflammatory Bowel Disease - Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).10-08-2009
20090143468PET FOOD COMPOSITIONS AND METHODS - Presently described are compositions and methods which utilize stearidonic acid (SDA).06-04-2009
20100298435Stable Emulsions of Oils in Aqueous Solutions and Methods for Producing Same - Methods for making highly stable, oxidation-resistant emulsions comprising an oil, an emulsifier, an emulsion stabilizer and water are provided. The invention is particularly well suited for oils that are susceptible to oxidation, such as long chain polyunsaturated fatty acid oils. The resulting emulsion is highly stable and resistant to oxidation, and is useful in a number of products and as a stand-alone product.11-25-2010
20100298434NEUROPROTECTION AND PREVENTION OF DOPAMINERGIC CELL DEATH BY TARGETING NUR77 TRANSLOCATION - There is provided methods for the prevention of dopaminergic cell death for neuroprotection and the prevention or slow down of progression of Parkinson's disease. Particularly, the invention relates to methods for protecting and/or preventing dopaminergic cell death by the administration of a compound or agent inhibiting the translocation of Nur77 to the cytosol of dopaminergic cells. The invention also relates to methods for identifying such compounds or agents.11-25-2010
20130131173COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID SUITABLE FOR HIGH PURIFICATION - The invention relates to a microbial biomass composition produced from a heterotrophic fermentation whose fatty acid profile exhibits: an eicosapentaenoic acid (EPA) to arachidonic acid (ARA) ratio of about 11:1 or more; an EPA to total co-concentrating fatty acid ratio of about 8:1 or more, extract compositions, and methods of producing such compositions.05-23-2013
20090069426Methods For Reducing The Amount Of A Proinflammatory Substance In Animal Tissue Or Body Fluid - A method for reducing the amount of a proinflammatory substance present at an elevated level in animal tissue or body fluid by orally administering to the animal a proinflammatory substance reducing amount of a composition comprising at least one omega-3 fatty acid. The method is useful for reducing inflammation caused by elevated levels of proinflammatory substances including inflammation associated with an oral condition.03-12-2009
20090069425Active composition for treatment or prevention of problems related to a disturbance of the biological clock - A composition contains polyunsaturated fatty acids and flavonoids as active substances. A method treats disorders caused by disturbance of a biological clock in humans and animals and includes administering a therapeutically effective amount of the composition to a human or animal. A method regulates the biological clock in a mammal and includes administering a therapeutically effective amount of the composition to the mammal.03-12-2009
20110130458KRILL OIL PROCESS - The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of fatty acids with chain length C14 and C16.06-02-2011
20110213032FATTY ACID C16: 1N7-PALMITOLEATE A LIPOKINE AND BIOMARKER FOR METABOLIC STATUS - The present invention provides for a novel lipokine, C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, a low concentration of C16:1n7-palmitoleate in the free acid component of the serum indicates a risk of metabolic disease, and that de novo lipogenesis should be stimulated. Additionally, administering C16:1n7-palmitoleate to a subject (via nutraceutical or other means), positively impacts lipid metabolism.09-01-2011
20110039931METHOD OF TREATING ANIMAL'S EXTERIOR FOR CLEANING AND/OR INSECT REPELLENCY - A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal The composition includes a nonionic primary surfactant comprising an ethoxylated sorbitol oleate, a nonionic secondary surfactant, and water. The nonionic secondary surfactant is selected from the group consisting of linear ethoxylated secondary alcohols, polyoxyethylene ethers, ethoxylated sorbitan monolaurtes, ethoxylated fatty acid amides and ethoxylated fatty acids that contain about 7 moles to about 26 moles of ethylene oxide and comprise from about 20 to about 36 weight percent of said composition. The water is in a sufficient amount so that the nonionic primary and secondary surfactants together with the water form a gel.02-17-2011
20110118351Stabilized Formulations of Fatty Acids - Disclosed herein are stabilized powder and aqueous formulations comprising a substantially water insoluble lipophilic bioactive compound and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a water insoluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.05-19-2011
20090203788METHOD OF ENHANCING REPRODUCTIVE FUNCTION OF MAMMALS BY FEEDING OF CONJUGATED LINOLEIC ACIDS - This invention provides methods for improving reproductive performance of lactating dairy cows and other mammals. The method in the case of cows comprises feeding to the cows, a composition comprising conjugated linoleic acids (CLAs), cis-9, trans-11 and trans-10, cis-12. When these CLAs are fed daily to dairy cows starting at or prior to calving, and continued after parturition, an improvement in reproductive performance is observed.08-13-2009
20110086919HIGH EICOSAPENTAENOIC ACID PRODUCING STRAINS OF YARROWIA LIPOLYTICA - Engineered strains of the oleaginous yeast 04-14-2011
20090182050Salts of Fatty Acids and Methods of Making and Using thereof - Disclosed are methods of making salts of fatty acids (e.g., marine oils) and to salts prepared by the disclosed methods. Methods of using the disclosed salts are also disclosed.07-16-2009
20090082448METHOD FOR PLACENTAL EXFOLIATION USING OXO-ARACHIDONIC ACID OR THE LIKE - A composition for placental exfoliation and a method for placental exfoliation. The composition for placental exfoliation contains an arachidonic acid derivative or the like, and the method for placental exfoliation comprises the step of administering an arachidonic acid derivative or the like to a mammal after the fetal delivery.03-26-2009
20090042985Process for the Preparation of Fatty Acids - process for the preparation of a material comprising conjugated isomers of a polyunsaturated fatty acid comprises: treating a first fatty acid mixture comprising saturated fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids in the presence of ethanol to form (i) a solid fraction and (ii) a liquid fraction comprising a second fatty acid mixture, wherein the second fatty acid mixture has a higher molar ratio of total polyunsaturated fatty acids to total saturated and monounsaturated fatty acids than the first fatty acid mixture; separating the solid fraction and the liquid fraction; and subjecting the second fatty acid mixture or a derivative or reaction product thereof to treatment with a base in the presence of a solvent, to form conjugated isomers of at least some of the polyunsaturated fatty acids.02-12-2009
20090036533ANTIBACTERIAL AGENT COMPRISING 7, 10-DIHYDROXY-8(E)-OCTADECENOIC ACID - The present invention relates to an antibacterial agent containing 7,10-dihydroxy-8(E)-octadecenoic acid (referred as DOD) as an active ingredient. DOD produced by the method of the present invention can be effectively used as an antibacterial agent because it has a wide spectrum of antibacterial activity against various microorganisms.02-05-2009
20090215897Method for treatment and prevention of respiratory insufficiency - The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite induced respiratory insufficiency and/or dust mite allergy.08-27-2009
20090215895Therapeutic and carrier molecules - The present invention relates generally to compounds comprising a hydrocarbon chain portion and more particular to compounds comprising chemical derivatizations of the hydrocarbon chain which are useful therapeutic and prophylactic molecules. The present invention further provides compounds where the hydrocarbon chain portion is a carrier molecule for functional groups, moieties or agents. The compounds of the present invention are particularly useful in the treatment and prophylaxis of a range of conditions including cancers, protein kinase c(PKC)- or NFkB-related- or -associated conditions, cardiovascular conditions, pain, inflammatory conditions, vascular or immunological conditions such as diabetes, neurological conditions and infection by a range of viruses or prokaryotic or eukaryotic organisms. The present invention further provides pharmaceutical compositions and methods of medical treatment.08-27-2009
20090215896REELIN DEFICIENCY OR DYSFUNCTION AND METHODS RELATED THERETO - A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs—unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs—unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentacnoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.08-27-2009
20110098358HUMAN BETA3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME - A human adrenergic β04-28-2011
20110152371ANTIOXIDANT EXTRACT FROM FRUIT SKINS - The application generally relates to methods of inhibition of oxidation of polyunsaturated fatty acid—(PUFA) and/or lipid-containing foods and nutraceutical products. The application provides natural and consumer friendly method for preventing the oxidation or rancidity development of PUFA and/or lipids by incorporation of apple skin extracts as natural antioxidant in emulsions, bulk oil or other form of food and nutraceutical products.06-23-2011
20130158120STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.06-20-2013
20110251278MICROALGAE EXTRACT CONTAINING OMEGA 3-POLYUNSATURATED FATTY ACIDS AND METHOD FOR EXTRACTING OIL FROM MICRO-ORGANISMS - The present invention relates to a biphasic microalgae extract comprising 15-95 wt. % of an aqueous phase and 5-85 wt. % of an oil phase, said extract containing at least 1% by weight of total fatty acids of ω3-fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and combinations thereof, said extract further being characterized in that it contains: • 40-100% by weight of the oil phase of lipids selected from triglycerides, diglycerides, monoglycerides, phosphatides, free fatty acids and combinations thereof; • 0.01-10% of carotenoids by weight of the oil phase; • 0.5-10% of sodium chloride by weight of the aqueous phase; • 0-3 wt. % of non-dissolved material other than dispersed droplets of aqueous phase or oil phase; and • 0-10% of C10-13-2011
20110009488Lipoxin A4 Protection for Cornea Endothelial Cells - Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that can be topically administered to decrease the swelling of the cornea or maintain the clarity of the cornea. Lipoxin A4 or its analogs can also be combined with other known nutritive compounds to form a solution for storage of a cornea prior to transplantation.01-13-2011
20110082207Inhibitors of Yeast Filamentous Growth and Method of Their Manufacture - The invention broadly relates to the use of α,β-unsaturated fatty acids to inhibit the filamentous growth of fungi and yeasts and to a method for producing same. In particular the invention relates to the use of optionally substituted C8 to CI5 α,β-unsaturated fatty acids or salts, esters or amides thereof for inhibiting or retarding the yeast-to-mycelium transition of organisms having a dimorphic life cycle.04-07-2011
20110082206HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS - Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.04-07-2011
20110077302ENZYMATIC SYNTHESIS OF SPHINGOLIPIDS - The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphingolipids or compositions.03-31-2011
20080306155METHOD FOR TREATING RENAL DISEASE - A method preserving renal medullary blood flow in a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE analog to the human or non-human animal in an amount sufficient to attenuate a fall in renal medullary blood flow following a renal disorder. In addition, a method for preventing and treating ischemic acute renal failure is disclosed. The method involves administering 20-HETE or a 20-HETE agonist to the human or non-human animal in an amount sufficient to prevent or treat ischemic acute renal failure.12-11-2008
20120149775METHODS FOR PREVENTING AND IMPROVING SKIN ELASTIC PROPERTY LOSS - The present invention is directed to method for preventing and improving an aggravation of a skin condition accompanied with a skin elastic property loss by suppressing an increase in, or inhibiting the physiological activity of, palmitic acid. The present invention provides a cosmetic method for preventing and improving wrinkling and sagging accompanied with a skin elastic property loss and a method for preventing and treating a wound healing disorder and a bedsore.06-14-2012
20120149774COMPOSITIONS AND METHODS FOR NUTRIENT DELIVERY - The present disclosure provides compositions and methods for delivering nutrients to subjects requiring small-volume nutritional support, such as preterm infants. The compositions may comprise an emulsion of docosahexaenoic acid (DHA) and arachidonic acid (ARA). The nutritional compositions are useful, for example, in correcting nutritional deficiencies by increasing a subject's intake of nutrients, such as ω-3 or ω-6 long-chain polyunsaturated acids. The nutritional compositions are suitable for enteral delivery as a nutritional supplement or for oral delivery as a human milk or infant formula fortifier.06-14-2012
20110039932POLYUNSATURATED FATTY ACID MONOVALENT AND DIVALENT METAL SALT SYNTHESIS - Methods for the preparation of a free-flowing, storage-stable fatty acid metal salt product by forming a reactive admixture of (a) an unsaturated fatty acid glyceride feedstock; and (b) from about 1 mol to about 3 mol of at least one monovalent metal hydroxide or at least one divalent metal hydroxide; and heating the admixture to a temperature at which said fatty acid glycerides saponify to form fatty acid metals salts; wherein said monovalent metal is potassium; and wherein said divalent metal is selected from the group consisting of calcium, copper, magnesium and zinc. The fatty acid glycerides are saponified in an atmosphere in which the partial pressure of oxygen has been reduced by an amount effective to provide an improvement in storage stability until a free-flowing, storage-stage product is obtained. Storage stable metal salts of unsaturated fatty acids prepared by the inventive methods are also disclosed.02-17-2011
20100280115COMPOSITIONS OF HUMAN LIPIDS AND METHODS OF MAKING AND USING SAME - The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion.11-04-2010
20090182049Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans - A method for the treatment or prophylaxis of hypertriglyceridemia and hypercholesterolemia without concomitantly increasing LDL-serum cholesterol, in a human subject requiring such treatment, which method comprises orally administering to the patient an effective amount of a pharmaceutical composition in which the active ingredients comprise a mixture of fatty acids, wherein said mixture comprises at least about 60% by weight a combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from about 1.4:1 to about 5:1, wherein said combination is at least about 60% in the triglyceride form of the fatty acids and the balance is at least about 80% of mono and di-glycerides.07-16-2009
20090111877Methods for Enhancing the Quality of Life of a Senior Animal - Methods for enhancing the quality of life of a senior or super senior animal by feeding the animal a composition comprising at least one omega-3 polyunsaturated fatty acid and various combinations of amino acids, minerals, and antioxidants in amounts effective to enhance alertness, improve vitality, protect cartilage, maintain muscle mass, enhance digestibility, and improve skin and pelage quality. Changes in expression of genes associated with several biological pathways induced in an animal by feeding it said composition are consistent with an enhanced quality of life.04-30-2009
20090105342PUFA SUPPLEMENTS - Edible formulations, such as polyunsaturated fatty acids (PUFAs) such as pharmaceutical compositions or nutritional supplements, are disclosed comprising arachidonic acid (ARA). They are adapted to deliver from 150 mg to 1 g per day of ARA and may contain other PUFAs, for example docosahexaenoic acid (DHA). The DHA dosage is from 400 to 600 mg per day, and the ratio of ARA:DHA may be from 1:5 to 5:1. Pharmaceutical compositions comprising ARA and DHA at a ratio of ARA:DHA of 1:1 to 1:2 are also disclosed, as are foodstuffs comprising 0.1 to 5% ARA. Such formulations can be used to increase ARA levels in vivo, for example in pregnant women or for people who have diseases or conditions associated with low ARA levels.04-23-2009
20110257268Reduction of Sterols and Other Compounds from Oils - A process for the removal of sterols, specifically cholesterol, from a triglyceride oil, preferably a marine triglyceride oil, said process comprising contacting an oil with an adsorbent, specifically TRIS YL™, clay or a mixture thereof, heating the mixture to 100° C. to 210° C., preferably 150° C. to 170° C., preferably for a time period of greater than one minute and optionally at a pressure less than 133 Pa, preferably less than 1.33 Pa.10-20-2011
20110054030USE OF EICOSAPENTAENOIC ACID AND/OR DOCOSAHEXAHENOIC ACID IN WOMEN WITH ENDOMETRIOSIS - The present invention pertains to the use of essential fatty acids for the preparation of a food composition for treating in particular post-surgical pain and/or pain due to a post-surgical relapse in women having undergone an operation for endometriosis. Said essential fatty acids are preferably selected from the group consisting of long-chain polyunsaturated fatty acids of the omega-3 series, and in particular from the group comprising EPA and/or DHA.03-03-2011
20110054029WATER-SOLUBLE DIETARY FATTY ACIDS - Water-soluble dietary fatty acid formulations, solutions, and methods for increasing the water solubility and/or bioavailability of dietary fatty acids, as well as methods for treating various diseases are disclosed.03-03-2011
20110054028SUPPLEMENT FOR REDUCING HIV TRANSMISSION AND METHOD THEREOF - There is an urgent need for a method to reduce the risk of mother-to-child transmission (MTCT) of HIV during breastfeeding in HIV pandemic regions. The present invention provides a supplement for reducing the chance of transmitting HIV during MTCT and method thereof. The supplement comprising arachidonic acid (AA) alone, or a mixture of AA and DHA at safe intake doses. The supplement is provided to either the breastfeeding mothers or the babies to maintain cell membrane potential polarization through activation of the background potassium channels, thereby reducing the risk of HIV transmission.03-03-2011
20120302639OMEGA 3 FORMULATIONS FOR TREATMENT OF RISK FACTORS FOR CARDIOVASCULAR DISEASE AND PROTECTION AGAINST SUDDEN DEATH - A formulation for treating omega-3 fatty acid deficiency is disclosed containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. EPA+DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA) and of omega-3 fatty acids having 18 carbon atoms, including one or more of stearidonic acid (SDA) and alpha-linolenic acid (ALA).11-29-2012
20110263708Over-production of dihomo linolenic acid by a mutant strain of parietochloris incisa - The present invention is primarily directed to a mutant strain of 10-27-2011
20100324138Lipoxin A4 Protection for Retinal Cells - Lipoxin A4 and its analogs have been found to be effective in inhibiting apoptosis of retinal pigment epithelial cells induced by oxidative stress. Thus lipoxin A4 and its analogs, for example, lipoxin A4 epimer 15, can be used to prevent and treat retinal diseases due to the progressive degeneration of photoreceptors and retinal pigment epithelial cells (RPE cells), e.g., the dry form of age-related macula degeneration. They can also be combined with other compounds known to prevent apoptosis in retinal pigment epithelial cells, e.g., docosahexaenoic acid and neuroprotectin D1.12-23-2010
20090176879Fatty acid desaturases from primula - The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are 07-09-2009
20100029766Blends Comprising a Substituted Fatty Acid or a Derivative Thereof - The invention concerns blends of a hydroquinone substituted poly unsaturated fatty acid (as present in Kombo nut oil) or a derivative thereof, which blends comprised: 02-04-2010
20100022649Pharmaceutical Composition and Procedure to Treat and Prevent Prostatic Hyperplasia and Prostatitis From the Royal Palm (Roystonea regia) Fruits - A method for treating and/or preventing BPH prostatitis, alopecia and hirsutism including administering a medication of the pharmaceutical composition obtained from the green or mature fruits of 01-28-2010
20100022646 METHOD OF NEUTRALISING ORGANOBORONATES WITH ACIDS - The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt or prodrug thereof. Also disclosed are intravenous formulations containing the specified compounds.01-28-2010
20100022648ORAL USE OF AT LEAST ONE MONOUNSATURATED FATTY ACID FOR HAIR IMPROVEMENT - The present invention relates to the cosmetic use by the oral route of at least one monounsaturated fatty acid, a salt thereof and/or an ester thereof, preferably petroselinic acid, for improving the quality of the hair and/or the appearance of the hair, in particular for preventing and/or treating the changes of the scalp and/or of the hair that occur with age.01-28-2010
20100016433NERVE-REGENERATING AGENT - A nerve-regenerating agent comprising, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a constituent fatty acid.01-21-2010
20100016432RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.01-21-2010
20080269329Process for Production of Microbial Fat/Oil Containing Discretional Amount of Diacylglycerol and Said Fat/Oil - In a process for the production of diacylglycerol-containing fat/oil where the ratio of diacylglycerol to the total neutral lipid is more than 20% by weight and a polyunsaturated fatty acid is a constituting fatty acid, a process which is characterized in that a microbe being able to produce said fat/oil is incubated and, if desired, said fat/oil is collected.10-30-2008
20080275119Treatment and Prevention of Liver Disease Associated with Parenteral Nutrition (PN) - The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months.11-06-2008
20100298433BRANCHED CHAIN FATTY ACIDS FOR PREVENTION OR TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent 5 or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes 10 over 25 wt % of the one or more branched chain fatty acid.11-25-2010
20090176880Methods for Culturing Human Lung Mast Cells and Uses Thereof - Methods for culturing human lung mast cells in the absence of co-culture with feeder cells which are viable for longer than 4 days are provided. Also provided are methods for using these human lung mast cell cultures to assess biological and pharmacological activities of these cells in vivo and to identify modulators of the survival, proliferation, function and phenotypic expression of human lung mast cells. Modulators identified via these cells are useful in the prevention and treatment of diseases involving human lung mast cell function.07-09-2009
20090093543OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA FOR HIGH EICOSAPENTAENOIC ACID PRODUCTION - Engineered strains of the oleaginous yeast 04-09-2009
20100069492PRODUCTION OF ULTRAPURE EPA AND POLAR LIPIDS FROM LARGELY HETEROTROPHIC CULTURE - Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like 03-18-2010
20100130611OMEGA 3 FATTY ACID FORMULATIONS - The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.05-27-2010
20110112191OXYLIPINS FROM STEARIDONIC ACID AND GAMMA-LINOLENIC ACID AND METHODS OF MAKING AND USING SAME - Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.05-12-2011
20090036532DHA Enrichment Process - The present invention relates to a continuous process of DHA enrichment of a solution of fatty acids or derivatives thereof comprising less than 50% of DHA relative to the total fatty acids of the solution or to derivatives thereof, wherein the process comprises the steps of (a) simultaneous countercurrent injection, into a fractionation column, of the flow of the solution of fatty acids or of derivatives thereof and of a flow of supercritical CO02-05-2009
20120065263RETROVIRUS-INFECTION INHIBITOR - An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.03-15-2012
20090036531Method for treatment of onychomycosis - Onychomycosis is treated by grinding the infected portion of a nail down to a level where the nail is not infected and applying a coating of a cyanoacrylate ester to the ground portion which cures to a hard layer. The hard layer can be successively ground and coated with successive layers of cycanoacrylate.02-05-2009
20090054523Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases - A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided.02-26-2009
20090275658Method for Producing a Raw Oil from Mixtures of Micro-Organisms and Plants, Oil Produced According to Said Method and Specific Uses of the Thus Produced Oil and, Optionally, Additional Refined Oil - The invention relates to a method for producing a raw oil from micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil in foodstuffs, in food supplements, or in cosmetic or pharmaceutical compositions.11-05-2009
20120046363DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF HEART FAILURE - There is currently no completely effective treatment for heart failure. Considering the need for, and current void in the medical field for, a treatment for heart failure, the invention is drawn to treating heart failure. In particular aspects, the invention is drawn to the discovery that certain polyunsaturated fatty acids (PUFAs) and doses thereof are useful for treating heart failure. In other particular aspects, the invention is drawn to the discovery that certain PUFAs and doses thereof are useful for preserving mitochondrial function in a heart failure subject.02-23-2012
20090099259Method for regulating gene expression - The present invention is directed to a novel method for modulating the expression of one or more genes in a subject by administering an amount of DHA and ARA to the subject.04-16-2009
20090221705OMEGA 3 - A process for the preparation of a water soluble unsaturated fatty acid salt from a crude composition comprising at least one non-water soluble or sparingly water soluble unsaturated fatty acid or salt thereof, said process comprising: adding to said crude composition in the presence of water at least one amino alcohol compound so as to form a water soluble amino alcohol salt of said acid or salt; separating an aqueous phase; and optionally isolating said salt from said aqueous phase.09-03-2009
20120108662COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS - The present application relates to compositions and the treatment of skin disorders, dry skin, protection of skin in inflammatory events and neurological disorders. The present application more particularly discloses the identification of new genes and metabolic pathways involved in skin disorders, which provide novel targets and approaches for treating said disorders and for screening biologically active compounds. The present invention also provides various products and constructs, such as probes, primers, vectors, recombinant cells, which can be used to implement the above methods. The invention may be used to detect or treat various skin disorders, particularly dry and inflammatory skin disorders and neurological disorders, in various subjects, including mammalian subjects, particularly human beings.05-03-2012
20120010289METHOD FOR PLACENTAL EXFOLIATION USING OXO-ARACHIDONIC ACID OR THE LIKE - A composition for placental exfoliation and a method for placental exfoliation. The composition for placental exfoliation contains an arachidonic acid derivative or the like, and the method for placental exfoliation comprises the step of administering an arachidonic acid derivative or the like to a mammal after the fetal delivery.01-12-2012
20110166228COMPOSITION - The present invention relates to compositions comprising at least omega-3 lipid compounds substituted at the 2-positions having therapeutic activity. More specifically, the present invention relates to a composition comprising at least omega-3 lipid compounds substituted at the 2-position, counted from the functional group (X) of the omega-3 lipid compound, wherein the omega-3 lipid compounds comprise: a compound of general formula (I):07-07-2011
20110166229PREVENTION OF PSYCHOTIC DISORDERS AND/OR TREATMENT OF PSYCHOTIC SYMPTOMS - The present invention relates to methods of preventing a psychotic disorder in a subject in need of intervention including administering to the subject a composition including EPA (eicosapentanoic acid) and DHA (docosahexaenoic acid). Methods of treating pre-psychotic symptoms in a subject, including administering to the subject a composition including EPA and DHA are also included.07-07-2011
20120016027Composition and Method for Improved Lens Comfort - The present invention relates to methods of preventing ocular discomfort, improving ocular comfort or ameliorating decrease in ocular comfort during wearing of an ophthalmic device (such as a contact lens), that include the administration of compositions comprising fatty acids, such as omega-3 and/or -6 fatty acids. The present invention also relates to fatty acid compositions suitable for use in the methods of the present invention.01-19-2012
20120016026Compositions containing non-polar compounds - Provided are compositions and methods for producing stable foods and beverages that contain high concentrations of additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.01-19-2012
20120115955Methods for tumor treatment and adipogenesis differentiation - The present invention provides methods and pharmaceutical compositions for treating tumors.05-10-2012
20120059061NOVEL ANTI-INFLAMMATORY COMPOUNDS - An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.03-08-2012
20120157529Composition and Method for Prevention, Mitigation or Treatment of an Enteropathogenic Bacterial Infection - The present invention embraces the use of palmitoleic acid, or a derivative, mimetic, or extract containing the same, to decrease the expression of bacterial virulence factors thereby preventing, mitigating, or treating bacterial infection.06-21-2012
20110092594USE OF NITRATED LIPIDS FOR TREATMENT OF LIPID DISORDERS AND OBESITY, AND LIPID- AND OBESITY-RELATED CONDITIONS - The present invention relates to methods of treating lipid disorders, lipid-related disorders or conditions, obesity and obesity-related disorders using nitrated lipids. In particular, the methods comprise administering effective amounts of nitrated fatty acids or esters thereof in order to reduce one or more of triglycerides, free fatty acids, body weight, cholesterol, urine protein excretion and oxidative stress or increase the level of plasma HDL in a subject.04-21-2011
20110092593Water-Soluble Colonoscopy Lubricant - Disclosed is a water-soluble colonoscopy lubricant essentially comprising Polyethylene Glycol 400; Propylene Glycol; and Glycerin. Distilled water may be added as needed to achieve a desired viscosity. Additional ingredients such as a preservative and a pH adjuster may also be added to the colonoscopy lubricant.04-21-2011
20120157531COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.06-21-2012
20120309831BALANCED FAT COMPOSITION AND USE THEREOF IN A LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR ENTERAL FEEDING - This invention relates to a balanced fat composition and use thereof in a liquid nutritional composition, in particular suitable for tube feeding. This invention further relates to said liquid nutritional composition for providing enteral nutrition to patients in need thereof, in particular for providing a complete enteral nutrition, in particular for providing a long-term enteral nutrition. More specifically, the balanced fat composition and the liquid nutritional composition comprising said balanced fat composition comprises specific amounts of linoleic acid (LA), alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), at least one medium chain fatty acid (MCFA), and at least one mono-unsaturated fatty acid (MUFA). The invention relates further to a method for providing enteral nutrition to patients in need thereof comprising administering an effective amount of said liquid nutritional composition comprising the balanced fat composition according to the invention.12-06-2012
20120157530METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.06-21-2012
20110065793HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES - A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.03-17-2011
20110105612METHOD AND COMPOSITION FOR LONG ACTING BACTERIAL SUPPRESSION ON SKIN - The present disclosure relates to methods and compositions for suppressing the growth of microorganisms on selected areas of the skin for an extended period of time, such as one hour, twenty four hours, seventy two hours, or longer. An area of the skin is selected for the suppression of the growth of microorganisms and a microorganism growth suppressing agent is topically applied to the selected area of the skin. The microorganism growth suppressing agent may be comprised in a pharmacologically acceptable vehicle such as an emulsion or soap. The microorganism growth suppressing agent comprises free conjugated fatty acid such as conjugated linoleic acid.05-05-2011
20120122983DEODORIZED EDIBLE OIL OR FAT WITH LOW LEVELS OF BOUND MCPD AND PROCESS OF MAKING BY CARBOXYMETHYL CELLULOSE AND/OR RESIN PURIFICATION - A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of contacting the oil or fat to a carboxymethyl cellulose or an ion exchange resin. The carboxymethyl cellulose can be a Blanose® cellulose gum and the resin can be a cationic resin. A deodorized vegetable oil or fat and a food product made there from is described. The food product can be an infant formula. It exhibits low levels of bound MCPD and/or low level of bound 3-MCPD. In one embodiment the oil or fat has a reduced level of free fatty acid as well as a limpid aspect and no off-flavors.05-17-2012
20120122982USE OF PUFAS TO TREAT NERVE DAMAGE - The present invention provides use of compounds which are polyunsaturated fatty acid (PUFA) derivatives of formula (I), in the form of racemates, stereoisomers or mixtures of stereoisomers, or pharmaceutically acceptable salts, or solvates thereof, wherein -AIk- is —(CH05-17-2012
20110184063Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of γ-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-β1/TNF-α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as γ-linolenic acid.07-28-2011
20110184064THERAPEUTIC AGENT FOR HEPATITIS C - Disclosed is a novel therapeutic means against interferon-resistant hepatitis C. Specifically disclosed are: a pharmaceutical composition for treating interferon-resistant hepatitis C, which is characterized by comprising at least one component selected from the group consisting of an ω-3 polyunsaturated fatty acid, a pharmaceutically acceptable salt of the fatty acid and an ester of the fatty acid as an active ingredient; and a method for utilizing the pharmaceutical composition.07-28-2011
20120220659MEDICAMENT HAVING PROMOTING ACTION ON HEPATOCYTE PROLIFERATION - A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.08-30-2012
20120129937SOLUBILIZER FOR COSMETIC PREPARATIONS - The present invention relates to a mixture comprising (i) one or a plurality of 1,2-alkane diols with 5 through 8 carbon atoms and (ii) one or a plurality of ammonium-, sodium- or potassium-R05-24-2012
20120129938Anti-oomycetes - The present invention relates to the use of compounds of general formula (I) or of a salt thereof as anti-oomycetes and to a method for combating plant pathogens using said compounds.05-24-2012
20120083530Thermally Stable Oil-in-Water Emulsions Containing an Oil That Contains Polyunsaturated Fatty Acids - The present invention relates to thermally stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of −40° C., and are free from a variation in particle size after 9 months in storage at a temperature of −40° C. to −15° C.04-05-2012
20120136057HYDROXY FATTY ACID COMPOUNDS AND USES THEREOF FOR DISEASE TREATMENT AND DIAGNOSIS - A compound of formula (I): wherein R represents a hydroxy substituted C05-31-2012
20120172444Use of Conjugated Linoleic Acid - Conjugated linoleic acid (CLA) or a derivative thereof may be used in reducing the rate of increase of fat mass in a growing child.07-05-2012
20120172445NUTRITIONAL PRODUCTS INCLUDING A NOVEL FAT SYSTEM INCLUDING FATTY ACIDS - Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.07-05-2012
20100048706Ethoxylated and/or Hydrogenated Oil Adduct - A composition of matter comprising an oil adduct synthesized by an oil and an addition material, wherein the oil includes at least one member chosen from an ethoxylated oil, a hydrogenated oil, and an ethoxylated and hydrogenated oil: wherein the average degree of ethoxylation in the ethoxylated (optionally hydrogenated) oil is less than about 10 based on moles of ethylene oxide per mole of oil: wherein the hydrogenated (optionally ethoxylated) oil has an iodine value of less than about 75: wherein the oil is capable of undergoing reaction with the addition material through a hydroxyl group of tile oil; and wherein the addition material includes at least one member chosen from carboxylic acid anhydrides, maleic anhydride, dicarboxylic acids, fumaric acid, maleic acid, succinic acids alpha hydroxy acids, beta hydroxy acids, lactic acid, glycolic acid, lactobionic acid, carnitine, salicylic acid, and (meth)acrylic acid.02-25-2010
20100048705METHODS OF TREATING AND PREVENTING NEOVASCULARIZATION WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS - Disclosed are methods for treating or preventing ocular neovascularization in a subject at risk. The method comprises administering to the subject an effective amount of omega-3 polyunsaturated fatty acid to thereby treat or prevent the ocular neovascularization. This method is suitable for treating or preventing retinopathy of prematurity, retina vein occlusion, sickle cell retinopathy, choroidal neovascularization, radiation retinopathy, microangiopathy, retinal hyperoxia, diabetic retinopathy, and age related macular degeneration. Preferably the methods are applied to premature infants, especially those exposed to high levels of oxygen, to treat or prevent ocular neovascularization results from retinopathy of prematurity. Preferably, the omega-3 polyunsaturated fatty acid is administered at high dose, periodically (e.g. from birth) over a prolonged period of time, until the eye is fully vascularized, or to the age of 1 year. Appropriate routes of administration include oral and intravenous administration. Suitable omega-3 polyunsaturated fatty acids include docosahexaenoic acid and eicosapentaenoic acid. These agents can be administered in a pharmaceutically acceptable carrier, e.g. one which contains an anti-oxidant for the omega-3 polyunsaturated fatty acid.02-25-2010
20100048704PHARMACEUTICAL AND NUTRACEUTICAL PRODUCTS COMPRISING VITAMIN K2 - A pharmaceutical and nutraceutical product is provided comprising vitamin K02-25-2010
20120178813LIPID-LOWERING ANTIDIABETIC AGENT - A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.07-12-2012
20100292330COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION - The invention provides compositions comprising one or more long chain polyunsaturated fatty acids, nitric oxide releasing compounds, and medium chain triglycerides and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.11-18-2010
20120220660Composition With Preventive or Improvement Effect on Symptoms or Diseases Associated with Stress-Induced Behavior Disorders - A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.08-30-2012
20120259015MEDICAMENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF HEPATIC STEATOSIS OR NON-ALCOHOLIC STEATOHEPATITIS - A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.10-11-2012
20080300306Novel Compounds - Compounds of formula (I);12-04-2008
20110046222FATTY ACID AMIDES AND USES THEREOF - Provided are fatty acid amides of amino acids, uses thereof and pharmaceutical compositions including them.02-24-2011
20120101162METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY - Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition. In certain embodiments methods and compositions involve an aquaporin 7inducer.04-26-2012
20100022647HIGH ARACHIDONIC ACID PRODUCING STRAINS OF YARROWIA LIPOLYTICA - Engineered strains of the oleaginous yeast 01-28-2010
20130012583VINYL SUBSTITUTED FATTY ACIDS - Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.01-10-2013
20120149777COMPOSITIONS AND METHODS FOR IMPROVING CELLULAR SURVIVAL AND REDUCING APOPTOSIS AFTER ISCHEMIC EPISODE IN THE BRAIN - Compositions and methods for enhancing vascular integrity in animals are disclosed. The compositions and methods, which utilize long chain polyunsaturated fatty acids and nitric oxide releasing compounds are also effective for reducing ischemia-induced brain injury in an animal.06-14-2012
20120149776PREPARATION FOR SUN PROTECTION - The invention relates to the use of norbixin and an urucum extract enriched in bixin and/or norbixin as a food. The invention also provides a food preparation comprising norbixin, bixin or an extract comprising at least bixin or norbixin, the preparation being intended to be administered orally, for the protection of mammalian skin against UV-radiation.06-14-2012
20080234377POLYUNSATURATED FATTY ACIDS FOR TREATMENT OF DEMENTIA AND PRE-DEMENTIA-RELATED CONDITIONS - Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.09-25-2008
20080227860Composition Comprising Oleic Acid and the Use Thereof - The present invention relates to the pharmaceutical composition and health care food comprising oleic acid having neuroprotective activity. The oleic acid of the present invention has potent neuroprotective effect and recovery effect on neurological behavior. Therefore, it is useful as the therapeutics for the prevention or treatment of degenerative brain diseases in human or mammal.09-18-2008
20110263709METHOD FOR OBTAINING POLYUNSATURATED FATTY ACID-CONTAINING COMPOSITIONS FROM MICROBIAL BIOMASS - A method is disclosed for obtaining a refined lipid composition comprising at least one polyunsaturated fatty acid from a microbial biomass, wherein the refined lipid composition comprises at least one polyunsaturated fatty acid and is enriched in triacylglycerols relative to the oil composition of the microbial biomass.10-27-2011
20130178530Nutritional Compensation For Western-Type Diet - Disclosed is the use of a composition comprising docosahexaenoic acid (DHA) and/or arachidonic acid (ARA) in human subjects that are on the typical ‘Western-type” high-fat high-sugar diet. It was found, in a humanized animal model, that said composition is capable of compensating for one or more of the adverse health effects of said diet. Particularly, an effect was found in body weight reduction, without a lowering of food intake. The composition can be administered as an oral (pharmaceutical) dosage unit, as a nutritional supplement, or as a component in a food or drink.07-11-2013
20130137770INTRAVENOUS OMEGA-3 FATTY ACID COMPOSITIONS & METHOD OF USE - The invention encompasses intravenous pharmaceutical compositions containing omega-3 fatty acids and methods of treating traumatic brain injury, traumatic spinal cord injury and/or stroke using these pharmaceutical compositions.05-30-2013
20130096197METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.04-18-2013
20130102674METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.04-25-2013
20130102673METHOD OF TREATING AN EDIBLE OIL - A method of treating an edible oil to remove aldehydes comprises contacting the oil with an amino acid and an adsorbing agent. The amino acid and the adsorbing agent are contacted with the oil separately or as a mixture.04-25-2013
20130131172NOVEL ANTIMICROBIAL COMPOUNDS AND USES THEREOF - The present invention relates to novel antimicrobial compounds, methods of their production as well as uses thereof.05-23-2013
20130123363MEDICINAL AGENT FOR PREVENTION AND/OR TREATMENT OF HEPATOCELLULAR CARCINOMA - The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these.05-16-2013
20080200547Highly Purified Ethyl EPA and Other EPA Derivatives - A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.08-21-2008
20080200546Oral Composition For Enhancing Skin Properties - A stable consumable emulsion, comprising at least 50% water, 0.2 to 3 wt % of an oil comprising at least 12 wt % of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt % food-grade phospholipid emulsifier is provided which provides noticeable improvements in skin when consumed regularly.08-21-2008
20100286272Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications - Topical compositions comprising an effective amount of a nitroalkene and a carrier are used to prevent skin conditions or damage and to treat skin conditions and damage including rosacea, eczema, psoriasis, xerosis, dermatitis, seborrhea, thermal and radiation burns (including sunburn), acne, alopecia, skin aging, scars, and skin inflammation.11-11-2010
20100286271Nitro-alkyl Compound Compositions - Topical compositions to improve skin condition comprise an effective amount of a nitroalkene and a non-polar carrier. Preferred nitroalkenes are nitro-linoleic acid or nitro-oleic acid.11-11-2010
20110237669Polyunsaturated Fatty Acids Interactions and Oxidative Stress Disorders - This invention relates to the identification and treatment of the effects of products derived from oxidative pathways for polyunsaturated fatty acid (PUFA) metabolism, i.e., oxidative stress in a patient by monitoring the metabolism of DHA or by administering DHA.09-29-2011
20130150446ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS - The invention describes novel isolated, purified, 10,17-dihydroxy-docoosahexaenoic acids, esters, derivatives and their preparation.06-13-2013
20100317735HIGH EICOSAPENTAENOIC ACID OILS FROM IMPROVED OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA - Described are engineered strains of the oleaginous yeast 12-16-2010
20130184349METHOD FOR INCREASING PERFORMANCE OF OFFSPRING - Methods and compositions for increasing intestinal transport of nutrients or growth performance in the offspring of an animal are described. More specifically, a feed composition comprising an omega-3 fatty acid-containing composition for increasing intestinal transport of nutrients or growth performance in the offspring of the animal, and methods therefor, are described.07-18-2013
20120289600OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA FOR HIGH EICOSAPENTAENOIC ACID PRODUCTION - Engineered strains of the oleaginous yeast 11-15-2012
20120029080REDUCTION OF RISK OF OBESITY - A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.02-02-2012
20130197086PROCEDURE FOR THE OBTAINMENT OF FATTY ACIDS OF PHARMACOLOGICAL AND NUTRITIONAL INTEREST - This invention refers to a procedure for obtaining fatty acids of pharmacological and nutritional interest that comprises the steps of feeding a gas comprising CO08-01-2013
20130197087COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY - The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy.08-01-2013
20120295975METHODS OF TREATING INFLAMMATORY CONDITIONS - The present invention provides methods of treating a β-arrestin2 mediated and/or GPR120 mediated response in a subject. The β-arrestin2 mediated and/or GPR120 mediated response can be inflammation, including diabetes, inflammation associated with obesity and obesity. The methods can comprise administering to a subject a therapeutically effective amount of a compound predicted to bind a β-arrestin2 molecule and/or GPR120, wherein the compound selectively activates a β-arrestin2-dependent signaling pathway of GPR120.11-22-2012
20120088831Thraustochytrids, Fatty Acid Compositions, and Methods of Making and Uses Thereof - The present invention is directed to isolated thraustochytrid microorganisms as well as strains and mutants thereof. The invention is further directed to biomasses, microbial oils, compositions, cultures, methods of producing microbial oils, and methods of using the isolated thraustochytrids, biomasses, and microbial oils.04-12-2012
20120095099Trans carotenoids, their synthesis, formulation and uses - The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.04-19-2012
20120095098Bioavailability Enhancement Delivery System - A composition for increasing the bioavailability of drugs in humans and animals comprising a microemulsion further comprising a first emulsifier, a second emulsifier, and an oil wherein the emulsifiers have individual HLB values of between about 10 and about 30, are in a ratio ranging from about 1:1 to about 4:1; and, the first and second emulsifier combination and oil are in a ratio of about 99:1 to about 9:1. A method for increasing the bioavailability of such a composition is also provided.04-19-2012

Patent applications in class Carbon to carbon unsaturation